<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97483">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01947257</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A00730-45</org_study_id>
    <secondary_id>2013-19</secondary_id>
    <nct_id>NCT01947257</nct_id>
  </id_info>
  <brief_title>Is There a Correlation Between the Pulmonary Artery Pressure and the Acceleration of the Flow in the Pulmonary Artery Evaluated by Transesophageal Echocardiography (TOE) ?</brief_title>
  <official_title>Is There a Correlation Between the Pulmonary Artery Pressure and the Acceleration of the Flow in the Pulmonary Artery Evaluated by Transesophageal Echocardiography (TOE) ?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The measure of the pulmonary artery pressure (PAP) is a very useful index in intensive care
      to estimate right ventricular after load. The reference technique for this measure is the
      right catheterism which is an invasive technique. It is possible to estimate the pulmonary
      artery pressure by using transthoracic echocardiography (TTE) which allows, using the
      continuous Doppler, the measure of maximum speed of tricuspid regurgitation (TRvmax). The
      measure of the TRvmax can however be difficult for intensive care patients with little
      echogenicity or impossible for those having no tricuspid leak. The evaluation of the
      tricuspid regurgitation is also particularly difficult using TOE. To avoid these drawbacks,
      one can use the analysis of the pulmonary ejection in the pulmonary artery (PAAT) with TOE.
      However, the data of the literature are controversial on this method and it was not
      validated in mechanically ventilated intensive care patients.

      The aim of this work is to compare three methods of measure of the PAP: the measure TRVMAX
      (by means of the tricuspid leak) by transthoracic echocardiography, the measure of the TAAP
      by transesophageal ultrasound and the direct measure of the pulmonary pressures by right
      catheterization, in ventilated patients already monitored with a catheter in the right
      cavities for usual indications in intensive care (ARDS, shock). We shall analyze then the
      correlation between the TRVmax, the TAAP and the pressures measured by the right catheterism
      which serves as reference technique.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>measure of the pulmonary artery pressure</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment>50</enrollment>
  <condition>Ventilated Patients</condition>
  <arm_group>
    <arm_group_label>ventilated patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>the measure TRVMAX</intervention_name>
    <description>by transthoracic echocardiography</description>
    <arm_group_label>ventilated patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>the measure of the pulmonary artery</intervention_name>
    <description>by transesophageal ultrasound</description>
    <arm_group_label>ventilated patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>the direct measure of the pulmonary pressures</intervention_name>
    <description>by right catheterization</description>
    <arm_group_label>ventilated patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged over 18 years

          -  Admitted to intensive care

          -  Mechanically ventilated and sedated

          -  Carrying a right catheterization

          -  Making a ETO indicated by the medical team or doctor in charge of the patient

        Exclusion Criteria:

          -  Patients under 18 years

          -  expectant mother

          -  Patients without health insurance

          -  Refusal to close
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LOIC MONDOLONI</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>gilles PERRIN</last_name>
    <email>gilles.perrin@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>gilles perrin</last_name>
      <email>gilles.perrin@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>gilles perrin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 17, 2013</lastchanged_date>
  <firstreceived_date>July 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
